Primary and secondary endpoints
After a median follow-up of 266 days (IQR, 96 days), AF/atrial
tachycardia-free survival was 88% (Figure 2). Among the three subjects
experiencing recurrences (12%), one had persistent atrial tachycardia,
whereas the remaining two had both persistent AF and atrial tachycardia
over the course of follow-up.
The primary outcome was assessed by means of loop recorders in 7 (28%)
and pacemakers/defibrillators in 3 patients (12%), respectively.
Antiarrhythmic drugs were discontinued three months after CA in 22
subjects (88%); the three subjects who remained on antiarrhythmic
medications were treated with amiodarone. The AF/atrial tachycardia free
survival off-antiarrhythmic drugs measured 80%.
The EHRA score significantly improved from baseline to 9-month follow-up
(median EHRA score at baseline, 3 [IQR, 2]; median EHRA score at
9-month follow-up, 1 [IQR, 1]; p=0.03, Figure 3), and the proportion
of patients with no symptoms (EHRA class I) significantly increased
during the same time interval (0/25 at baseline, 14/25 at 9-month
follow-up, p=0.02).